Centogene (NASDAQ:CNTG – Get Rating) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 263,200 shares, a growth of 4,961.5% from the April 15th total of 5,200 shares. Currently, 2.8% of the shares of the company are sold short. Based on an average daily trading volume, of 937,300 shares, the days-to-cover ratio is currently 0.3 days.
Hedge Funds Weigh In On Centogene
A hedge fund recently raised its stake in Centogene stock. Platinum Investment Management Ltd. boosted its stake in shares of Centogene (NASDAQ:CNTG – Get Rating) by 4.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,377,150 shares of the company’s stock after purchasing an additional 106,000 shares during the quarter. Platinum Investment Management Ltd. owned 8.78% of Centogene worth $2,662,000 at the end of the most recent quarter. Institutional investors own 11.17% of the company’s stock.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a “buy” rating and issued a $2.50 price objective on shares of Centogene in a research note on Wednesday, April 12th.
Centogene Price Performance
Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It operates through three segments: Pharmaceutical, Diagnostics, and COVID-19 testing.
- Get a free copy of the StockNews.com research report on Centogene (CNTG)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.